Bristol-Myers Squibb Co. (NYSE:BMY) – Investment analysts at Jefferies Group issued their Q3 2016 earnings per share estimates for shares of Bristol-Myers Squibb in a research note issued to investors on Thursday. Jefferies Group analyst J. Holford forecasts that the firm will post earnings of $0.64 per share for the quarter. Jefferies Group currently has a “Hold” rating and a $57.00 target price on the stock. Jefferies Group also issued estimates for Bristol-Myers Squibb’s FY2016 earnings at $2.62 EPS, FY2017 earnings at $2.76 EPS, FY2018 earnings at $3.02 EPS and FY2019 earnings at $3.96 EPS.
Other analysts also recently issued reports about the company. Citigroup Inc. decreased their price objective on Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, August 3rd. Leerink Swann restated a “buy” rating and issued a $85.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, July 29th. Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 price objective for the company in a report on Monday, July 25th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 price objective for the company in a report on Wednesday, July 13th. Finally, Berenberg Bank restated a “buy” rating on shares of Bristol-Myers Squibb in a report on Tuesday, July 12th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $69.31.
Shares of Bristol-Myers Squibb (NYSE:BMY) traded down 0.269% during mid-day trading on Friday, hitting $50.105. The stock had a trading volume of 8,276,780 shares. The firm’s 50 day moving average price is $55.35 and its 200 day moving average price is $66.40. Bristol-Myers Squibb has a 1-year low of $49.12 and a 1-year high of $77.12. The company has a market cap of $83.72 billion, a P/E ratio of 29.301 and a beta of 0.74.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.03. The company had revenue of $4.90 billion for the quarter, compared to analyst estimates of $4.60 billion. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.53 earnings per share.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Investors of record on Friday, October 7th will be issued a $0.38 dividend. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.03%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 87.36%.
In related news, Director Lamberto Andreotti sold 21,600 shares of Bristol-Myers Squibb stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $56.87, for a total value of $1,228,392.00. Following the sale, the director now owns 334,499 shares of the company’s stock, valued at approximately $19,022,958.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.24% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. WESPAC Advisors SoCal LLC raised its position in Bristol-Myers Squibb by 5.1% in the second quarter. WESPAC Advisors SoCal LLC now owns 1,538 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 75 shares in the last quarter. Perkins Coie Trust Co raised its position in Bristol-Myers Squibb by 3.1% in the third quarter. Perkins Coie Trust Co now owns 2,239 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 68 shares in the last quarter. Acropolis Investment Management LLC raised its position in Bristol-Myers Squibb by 21.3% in the third quarter. Acropolis Investment Management LLC now owns 2,815 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 495 shares in the last quarter. Jolley Asset Management LLC raised its position in Bristol-Myers Squibb by 4.0% in the second quarter. Jolley Asset Management LLC now owns 2,092 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 80 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in Bristol-Myers Squibb during the second quarter worth $163,000. Institutional investors and hedge funds own 72.88% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.